Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
December 09, 2019 16:10 ET
|
Equillium
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
November 26, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health
November 15, 2019 08:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Leadership Updates
November 12, 2019 16:07 ET
|
Equillium
Effective January 1, 2020 Bruce Steel will assume role of Chief Executive Officer, and Dan Bradbury will remain on the Board of Directors as Executive Chairman Krishna Polu, M.D., and Christine...
Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights
November 12, 2019 16:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium to Present at Investor Conferences in November 2019
November 07, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
November 06, 2019 08:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
October 01, 2019 16:05 ET
|
Equillium
Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC Company receives exclusive rights to negotiate licensing rights to develop and commercialize itolizumab...
Equillium to Host Business Update Call on October 1, 2019
September 17, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference
August 27, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...